X-Grant Pos Affect Intervention

Overview

This investigation aims to develop and evaluate a novel, accessible treatment delivering a) short-term, positive affect, in-person intervention resulting in clinically meaningful and significant reductions in depression and anxiety. We will also employ electroencephalography (EEG) to identify neurobiological predictors of responsivity to positive affect treatment. Participants will be determined as eligible if they score in the moderate range (or above) or in the bottom 25% of the depression or anxiety subscales of the DASS-21. Individuals with current or prior mania, psychosis, severe drug or alcohol use, neurodegenerative disease or traumatic brain injury or current risk for suicide are not eligible to participate.

Participants will spend approximately 3 hours during their first visit completing consent, selfreported questionnaires, and an EEG recording. All but the baseline control group will then be asked to spend another 3 hours during their last visit completing similar procedures. Three months after their last visit, all but the baseline control group will be asked to complete a followup assessment online which will take up to 1 hour to complete. Additionally, participants in the in-person intervention/active control groups will spend up to another 1 hour on the first session of the in-person intervention at the end of Study Visit 1 and spend 3-8 hours over the course of the week in between the first and second visit remotely completing additional study activities. These participants, if they have completed at least 50% of the daily activities, will be asked to spend up to another 1 hour for session 2 during the second visit and subsequently another 3-8 hours of activities over 1 week before being invited to the last visit.